Branchen
Pharma Manufacturing Outsourcing (CDMO)
Alle Analysen in Pharma Manufacturing Outsourcing (CDMO) — 4 Analysen.
51/100
Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success
Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.
48/100
48Buffett
WuXi XDC: Skalierung des ADC-Fertigungsnetzwerks
WuXi XDC ist ein in Hongkong notiertes Bioconjugate-CRDMO, das aus dem WuXi-Verbund ausgegliedert wurde und ADC-Discovery- sowie CMC-Arbeit in höherwertige Spätphasen- und kommerzielle Fertigung überführt; 2025 erreichte es einen Umsatz von 5.94 Milliarden RMB. Die Anlagedebatte dreht sich um den Preis, nicht um die ADC-Nachfrage: Der Auftragsbestand wuchs 2025 um 50.3% auf 1.489 Milliarden US-Dollar und der globale Marktanteil stieg von 9.9% im Jahr 2022 auf mehr als 24%, doch die Aktie handelt mit rund 37x dem nachlaufenden und 24x dem 2026er Gewinn, während sie einen anhaltenden geopolitischen WuXi-Abschlag und einen investitionsintensiven Schwenk in die überseeische kommerzielle Versorgung trägt. Bewertung Halten: Die ADC-CRDMO-Franchise ist stark und skaliert weiter, doch der aktuelle Preis nimmt bereits einen großen Teil der nächsten kommerziellen Etappe vorweg.
52/100
56Buffett
WuXi Biologics Deep Dive: A Biologics CRDMO Where Manufacturing Delivery Runs Ahead While Valuation Is Held Back by a Geopolitical Discount
WuXi Biologics is a global biologics CRDMO platform that uses a win-the-molecule model to carry early-stage programs all the way to late-stage commercial manufacturing, converting them into sticky back-end revenue. 2025 revenue reached RMB 21.79 billion, up 16.7% year on year, with back-end manufacturing already at 43.4% of revenue; yet 58.1% of revenue comes from North America, and the valuation is pinned at roughly 22x trailing earnings by a BIOSECURE-driven geopolitical discount. Rating Hold: manufacturing delivery is proven, but listing risk is not yet resolved and the margin of safety remains thin.
48/100
Lonza Group AG (LONN.SW) Zen Horizon Research Report
Lonza Group is a Basel-based Swiss biopharmaceutical CDMO founded in 1897 and now the world's second-largest biologics manufacturing outsourcer, with 2025 revenue of CHF 6.53B split between Biologics (70%, mAb / ADC / CGT / mRNA manufacturing) and Capsules & Health Ingredients (30%). The core thesis is that its 2024 strategic reset, including the USD 1.2B acquisition of Roche's Vacaville site in California, the divestiture of Specialty Ingredients, and the arrival of CEO Wolfgang Wienand, positions Lonza as one of only two scaled mammalian biologics capacity leaders above 200,000L, alongside Samsung Biologics, with additional policy tailwinds from the BIOSECURE Act against WuXi Biologics. Rating Hold: a high-quality CDMO compounder with visible recovery and upside catalysts, but a thin margin of safety at the current price.